Log in
Enquire now
‌

US Patent 11229633 Arimoclomol formulation

Patent 11229633 was granted and assigned to Orphazyme on January, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Orphazyme
Orphazyme
Current Assignee
Orphazyme
Orphazyme
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11229633
Patent Inventor Names
Thomas Kirkegaard Jensen0
Anders Mørkeberg Hinsby0
Carlos Roberto Camozzi0
Gert Mads Bolwig0
Date of Patent
January 25, 2022
Patent Application Number
16826733
Date Filed
March 23, 2020
Patent Primary Examiner
‌
Mark V Stevens
Patent abstract

The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11229633 Arimoclomol formulation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.